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converted into absolute value, as oppose to a gradual rise in the number of Mon2/ml,
the number of mDC2/ml remain gradually decreased with the progress of plaque
vulnerability. Plasma levels of Lp-PLA2, PTX3, FABP4 and myeloperoxidase, all of
which reﬂected coronary plaque vulnerability, were positively correlated with the
number of Mon2/ml, but negatively with the number of mDC2/ml.
Conclusions: Circulating subsets of mDC2 and Mon2 appear to be promosing
markers of plaque stabilization and rupture.
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Relationship between Stress Hyperglycemia and in hospital Mortality and
Complications in Patients with Acute Myocardial Infarction
Zhou Na, Li Zhen
First Afﬁliate Hospital Of Dalian University
Objectives: To investigate the effect of stress hyperglycemia on the mortality and
cardiovascular events in patients with acute myocardial infarction (AMI).
Methods: The study covered 1226 patients with the diagnosis of acute myocardial
Infarction admitted in CCU from January 2010 to December 2012 in the First
Afﬁliate Hospital of Dalian University. Based on the level of fasting blood glucose
(FBG), all patients were grouped into two groups: high blood glucose group (HBG
group, 7mmol/L) and non-high blood glucose group (non-HBG group, <7mmol/L).
Based on the history of diabetes were grouped into non-diabetes mellitus group
(NDM group) and diabetes mellitus group (DM group). According to the level of
FBG, patients within DM and NDM group were further divided into groupA
(FBG<7.0mmol/L), groupB (7.0mmol/LFBG<9.0mmol/L), groupC (9.0mmol/
LFBG<11.1mmol/L),groupD (FBG11.1mmol/L), respectively. Compare the dif-
ferences of the mortality and the rate of acute heart failure, cardiogenic shock and
main arrhythmias among these groups.
Results: The rate of high FBG is 34.1% in all AMI, among 37% patients without
history of diabetes mellitus. Compare with the 808 non-HBG groups patients, the 418
HBG group patients had higher mortality (9.1% vs 2.1%) and higher rate of acute
heart failure (37.8% vs 21.2%), cardiogenic shock (7.9% vs 0.7%) and main ar-
rhythmias (25.6% vs 16.5%) (all P<0.01). The mortality (6.4% vs 3.7%) and the rate
of acute heart failure (35.9% vs 23%) and cardiogenic shock (6.6% vs 1.7%) are
greater in the 362 DM group patients than the 864 NDM group (P<0.05).Among the
NDM group, the mortality and cardiovascular complications increased incrementally
with the increasing of FBG. Compared with groupA, the mortality and the rate of
acute heart failure, cardiogenic shock and main arrhythmias of groupB, groupC,
groupD are signiﬁcantly higher (all P<0.05). Compared with groupB, that mortality of
groupD increase obviously (30% vs 2.0%, P<0.01). In the DM group, the mortality
showed no signiﬁcant differences with the increased FBG levels, but the rate of acute
heart failure increased incrementally as FBG reached 9 mmol/L compared with group
A (P<0.01). The mortality of impaired fasting glucose (IFG) patients is similar to the
patients with normal FBG (2.4% vs 1.9%,P>0.05), and signiﬁcantly lower than the
patients with FBG7.0mmol/L (11.5% vs 2.4%,P<0.01).
Conclusions: The stress hyperglycemia could be used as a predictor of inhospital
mortality and cardiovascular events for patients with AMI. The elevation of FBG
increases the mortality and the incidence of acute heart failure, cardiogenic shock, and
main arrhythmias of patients with AMI. But the effects were not consistent between
DM and NDM patients. In NDM patients, as the FBG level increased, the mortality
increased signiﬁcantly, but this results was not obtained in DM group. In DM group,
the incidence of acute heart failure was signiﬁcantly increased as the FBG level
increased.
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The changes of PPARg and EPCs in patients with ACS complicated with
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Objectives: To observe the level of PPARg and EPCs in patients suffered from ACS
combined with Type-2 diabetes mellitus (T2DM) and ACS without T2DM, analysis
the relationship between PPARg, EPCs and ACS, T2DM, furthermore explore the
inﬂuence of Irbesartan on them to study the mechanisms of endothelial protection
beyond the antihypertensive effect of Irbesartan, hoping to ﬁnd a new treatment
method for ACS combined with T2DM.
Methods: 102 patients suffered from ACS was enrolled into our study, of which 52 of
them combined with T2DM (ACSDM group) and the other 50 patients only suffered
from ACS. Meanwhile, we selected 30 patients without coronary heat disease and
T2DM as the control group. To all patients, blood was drew when they were enrolled
to detect the level of PPARg and CD34+/CD309+ EPCs. All basic clinic data, CAG
and then Gensini score were compared among all groups. ACSDM group patients
were divided into A, B two group randomly. Patients, who were in A group, were
treated with Irbesartan 75mg po qd excepting conventional treatment of coronary heart
and diabetes. Patients, who wre in B group, were treated without Irbesartan. Blood
was drew again after 12 weeks. The level of PPARg was detected by enzyme-linked
immunosorbent method, meanwhile EPCs was detected by Flow cytometry instru-
ment. We analyed datas of each group by applicating of SPSS17.0.
Results: (1) The basic clinic data among each group, such as age, sex, body mass
index (BMI), smoking history, blood pressure, stain use, TG, HDL-CH, TC, LDL-CH,
blood urea nitrogen, creatinine were no difference (P all>0.05). CHD history, STEMI/
NSTEMI were no difference in ACS group and ACSDM group (P all>0.05). FPG,C126 JACC Vol 64/16/Suppl C j October 16–1HbA1c in the ACSDM group were signiﬁcantly much more than those in the ACS
group and control group (P <0.05). (2) The levels of PPARg of ACS group and
ACSDM group, when compared with control group (295.5625.06 ng/L), were
decreased signiﬁcantly (P all <0.05), and the ACSDM group was much lower than the
ACS group (P<0.05). (3) EPCs levels in ACS and ACSDM group were also
signiﬁcantly lower, when compared with control group (0.05840.0142%, and the
ACSDM group was much lower than the ACS group (P<0.05). 4 Gensini points in
ACSDM group was much higher than that of the ACS group (42.2425.46 VS.
30.2618.35, P<0.01). 5 Levels of PPARg and EPCs were signiﬁcatly correlated
positively (r¼0.658, P<0.01). Gensini scores of patients with ACS was correlated
negatively with both level of PPARg (r¼-0.484,P<0.05), and EPCs (r¼-
0.435,P<0.05). Levels of PPARg and EPCs in combined group were signiﬁcantly
correlated positively (r¼0.558, P<0.01). 6 After 12 weeks intervention of irbesartan,
the level of PPARg of A group increased signiﬁcantly compared with pre-treatment
levels [(226.1725.95) ng/L VS. (234.5526.20) ng/L, P<0.01], so did the level of
EPCs [(0.02840.0111) % VS. (0.03110.0102) %, P<0.01]. There was a signiﬁcant
positive relationship between them (r¼0.767, P<0.01). The level of PPARg and EPCs
of B group had on statistical difference after 12 weeks conventional treatment
(P all>0.05).
Conclusions: The level of PPARg, EPCs of patients with ACS are siganiﬁcantly
lower than those of control group, being much lower in ACSDM group. PPAR g and
EPCs level both decrease with the increasing of the degree of coronary artery stenosi.
Irbesartan, can improve the levels of PPARg and EPCs in patients with ACS and
T2DM, which probably become a new targets for therapeuty.
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Objectives: The correlation of enhanced platelet responder to clopidogrel with
bleeding outcome and entry-site complication has rarely been characterized in China
population undergoing percutaneous coronary intervention (PCI). The aim of present
study is to access the prognostic signiﬁcance of optimal platelet inhibition according
to a given clinical state and ethnicity.
Methods: A total of 278 non high risk acute coronary syndrome (ACS) patients
indicated for PCI were enrolled.Adenosine diphophate induced maximal platelet
aggregation (ADP-PG max) was assessed with Lumi-Aggregometer by light trans-
mission aggregometry method. The primary endpoint was the incidence of Throm-
bolysis in Myocardial Infarction (TIMI) deﬁned bleeding outcome and signiﬁcant
entry-site complication within hospital and 6 months follow-up period. Blood was
obtained for platelet aggregation 24h after PCI and 1 month follow up respectively.
Receiver-operating characteristic (ROC) curve analysis was conducted to reveal the
optimal platelet aggregation value deﬁning enhanced clopidogrel responder for as-
sociation of measurements with endpoints.
Results: A total of 24 patients (8.6%) met with primary endpoint in the study, while 4
(1.4%) TIMI major bleeding events, 11 (4.0%) minor bleeding events and 9 (3.2%)
signiﬁcant entry-site complications were observed. Follow-up ADP-PG max
(OR¼0.96, 95%CI, 0.93-0.99; p¼0.008) and renal insufﬁciency (OR¼3.38 95%CI,
1.26-9.19; p¼0.02) were associate with the prediction of bleeding events. The optimal
cutoff for follow up ADP-PG max was 24.5% [area under the curve 0.72 (95%
conﬁdence interval 0.59-0.85), p<0.001]. Bleeding occurred in 26.2% of patients with
clopidogrel enhanced response (16/61), as compared with 3.7% of remaining patients
(8/217), (hazard radio, 9.26; p<0.001).
Conclusions: In conclusion, enhanced clopidogrel responsiveness was associated with
a higher risk of bleeding and entry-site complication. Platelet function test detected at
an appropriate sampling time after clopidogrel administration may help identify high
bleeding risk patients after coronary intervention.
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Objectives: To investigate the potential mechanism accounting for the discrepancy of
VASP phosphorylation and platelet aggregation (PAG) in evaluating high on-clopi-
dogrel platelet reactivity in patients following ST segment-elevation myocardial
infarction (STEMI).
Methods: 90 consecutive STEMI patients scheduled for emergency percutaneous
coronary intervention (PCI) were enrolled. Platelet reactivity after clopidogrel loading
dose (300 mg) was determined by two methods [platelet reactivity index (PRI),
measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation ﬂow9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
